Searched for
US GENERICS BUSINESS
Sun Pharma’s specialty portfolio, Organon deal to drive growthSun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines....- Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosyst...
- Time to be be cautious in the market, convinced about the business: 5 large-cap stocks with upside potential of up to 22%This is the time to focus on businesses that have lived through storms like this before and come out the other side. The large, proven name...
- Sun Pharma Q2 profit takes a hit on exceptional itemsSun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue ...
- Sun Pharma Q2 profit falls 36% as litigation costs hit earningsSun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Reven...
- Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional chargesSun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported...
- Beyond Hotels: Salil Panigrahi on Building the Indian Ocean’s Next Lifestyle Ecosystem
- Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
- US, Brazil and Israel elections put India’s trade worth billions in focusRecent elections in the US, Brazil, and Israel may impact India's trade negotiations and economic partnerships. The US is close to finalizi...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla expects US business to draw support from upcoming product pipelineCipla reported a significant decline in its consolidated net profit for the second quarter of FY27. The company's North American revenue fe...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...
- India-US trade deal enters fine-tuning stage as most talks conclude, says Piyush GoyalIndia and the US are refining their bilateral trade agreement after concluding most discussions on the deal. Commerce Minister Piyush Goyal...
- PMS Talk: How Rs 50 lakh invested in Karma Capital in 2006 grew to Rs 5.4 croreIn this edition of ETMarkets PMS Talk, the co-founders discuss the lessons from their 20-year investment journey, how they identify compani...
- Dr Reddy's bets on generic semaglutide, biosimilarsDr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...
- Mark Cuban says AI hack agents are like cockroaches, but can be controlledCuban, famous for his role on business reality show "Shark Tank" and his involvement in the Dallas Mavericks NBA team, ventured into health...
- DRL says cap on trade margins a positive, posts 36% dip in Q2 PATIn the second quarter of FY2027, Dr. Reddy's Labs experienced a downturn in both revenue and profit. However, the company supports new trad...
- How a couple turned their first-date chilli oil recipe into a side hustle targeting $15,000 monthlyA homemade chilli oil recipe from a first date grew into Fiera Flavors, a food business founded by Mariana Carrizosa and Sebastian Jaramill...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
Load More
